Quick Answer
Atara Biotherapeutics, Inc. reported Research And Development Expense of $37.45 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed a decrease of -75.3% in Research And Development Expense from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2014 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2014 to 2025), Atara Biotherapeutics, Inc.'s Research And Development Expense has grown by 1,772.3%.
- Historical annual values: Fiscal year 2025: $37.45 million | Fiscal year 2024: $151.48 million | Fiscal year 2023: $224.79 million | Fiscal year 2022: $272.53 million | Fiscal year 2021: $282.00 million | Fiscal year 2020: $244.65 million | Fiscal year 2019: $216.10 million | Fiscal year 2018: $167.46 million | Fiscal year 2017: $81.21 million | Fiscal year 2016: $56.51 million | Fiscal year 2015: $41.62 million | Fiscal year 2014: $15.45 million | Fiscal year 2014: $2.00 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: